Insmed: Pioneering Patient-Centric Therapies for Chronic Diseases and Innovative Treatments

### Insmed's Commitment to Innovative Therapies: A Focus on Patient-Centric Solutions

Insmed Incorporated, a biopharmaceutical company headquartered in Bridgewater, New Jersey, is making significant strides in the development of therapies aimed at serious diseases, particularly those affecting pulmonary and inflammatory conditions. With a diverse portfolio that includes both approved and investigational drugs, Insmed’s commitment to innovation is evident in its ongoing research and development efforts. The company is on the forefront of creating first- and best-in-class therapies, underscored by its success in bringing two therapies for chronic lung diseases to market. This focus on addressing unmet medical needs positions Insmed as a key player in the biopharmaceutical landscape.

As Insmed prepares to present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026, it highlights its dedication to transparency and engagement with stakeholders. The live webcast of the presentation will serve as a platform to share updates on its pipeline and future strategic initiatives. This engagement is not only crucial for maintaining investor relations but also for fostering trust within the patient communities it serves. Insmed's efforts extend beyond simple product development; the company is committed to understanding and responding to the needs of patients, ensuring that its research aligns with real-world challenges faced by those suffering from chronic conditions.

In addition to its established therapies, Insmed is actively exploring advanced technologies in its early-stage programs. This includes innovative approaches such as gene therapy, AI-driven protein engineering, and RNA end-joining techniques. These initiatives reflect Insmed's forward-thinking philosophy and its desire to harness cutting-edge science to enhance treatment options for patients. By investing in research that pushes the boundaries of traditional biopharmaceutical approaches, Insmed is positioning itself to lead in the development of future therapies that could significantly improve patient outcomes.

Insmed's reputation as a top employer in the biopharmaceutical sector, recognized as the No. 1 Science Top Employer for five consecutive years, underscores its commitment to fostering a supportive work environment. The company maintains offices and research facilities across the U.S., Europe, and Japan, reinforcing its global presence and dedication to addressing health challenges on an international scale. Those interested in learning more about Insmed’s initiatives can access further information through its investor relations website and social media channels.